Roswell Park Cancer Institute (RPCI) is requesting support to continue its participation in the Cancer and Leukemia Group B (CALGB). The goals of our participation in CALGB include the following: (1) to continue our strong contribution to the scientific agenda of the Group, (2) to continue our performance of pilot activity at the local level that can be considered for Group adaptation, (3) to continue our administrative support for the efficient functioning of the Group, (4) to sustain accrual in order to allow the rapid accumulation of clinical data and experience through the cooperative group process, and (5) to continue to provide data of high quality in a timely manner. Over the last grant period, we have contributed substantially to the scientific, administrative, core, and publication activities of the CALGB. More specifically, 6 RPCI members serve or have served as chairs or vice chairs of scientific committees;16 serve or have served as members on scientific committees;12 serve or have served as study chairs or vice-chairs on 22 protocols;3 have protocols under consideration;9 provide or have provided core services to the Group;and 5 have performed pilot studies that have led to the development of CALGB protocols. RPCI members have contributed to 71 publications and given 58 education sessions. Furthermore, 8 members have or have had administrative roles in the Group. RPCI also represents an ongoing resource of ideas for future CALGB science;RPCI has a vigorous Phase I/I I program with many protocols potentially exportable to the Group. CALGB accrual by RPCI is customarily between 200-250 credits/year. Data quality and timeliness of submission has met Group standards. The campus spans 25 acres in downtown Buffalo and consists of 10 research and clinical buildings with approximately one million square feet of space. Statistics for fiscal year 2006-2007 include 6805 new cancer cases, 4215 hospital admissions, and 161,869 outpatient visits from patients in 36 states and 5 foreign countries. Both the inpatient and the outpatient centers are located in a spacious facility that opened in 1998.

Public Health Relevance

The aim of inter-Institutional cooperative clinical research, as exemplified by the CALGB, is to advance our understanding of malignant diseases and, thereby, improve our ability to treat people afflicted with them. Cooperative group research answers important therapeutic questions through large clinical trials and allows integration of information obtained from basic science and from economic and psychosocial investigations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
DeBoer, Rebecca; Koval, Gregory; Mulkey, Flora et al. (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298-306
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9

Showing the most recent 10 out of 58 publications